NOX 1.52% 6.7¢ noxopharm limited

Ann: Positive DARRT-1 Data in Late-Stage Prostate Cancer, page-25

  1. 3,387 Posts.
    lightbulb Created with Sketch. 294
    Dr Graham Kelly: It is exciting, although it needs to be said that this is early data. We're dealing with men who have reached the end of their disease process with prostate cancer. So, these are men who have exhausted all their available treatment options and they now typically have a matter of months to live. So, we are attempting to use our drug, Veyonda, to make radiation in these men much more effective and to offer something meaningful to them. And the data we're looking at suggests that that is what we're doing.


    stable for late conditions mean progress
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.